

- Kindblom L-G, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cell of Cajal. *Am J Pathol* 1998;152:1259–1269.
- Martin JF, Bazin P, Feroldi J, et al. Tumeurs myoïdes intra-murales de l'estomac. Considérations microscopiques à propos de 6 cas. *Ann Anat Pathol* 1960;5:484–497.
- Stout AP. Bizarre smooth muscle tumors of the stomach. *Cancer* 1967;15:400–409.
- Hirota S, Isozaki K, Moriyama Y, et al. Gain of function mutations of c-kit in human gastrointestinal stroma tumors. *Science* 1998;279:577–580.
- Corless CL. Gastrointestinal stromal tumors: what do we know now? *Mod Pathol* 2014;27:S1–S16.
- Barnett CM, Corless CL, Heinrich MC. Gastrointestinal stromal tumors: molecular markers and genetic subtypes. *Hematol Oncol Clin North Am* 2013;27:871–888.
- Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. *Lancet* 2013;382:973–983.
- Nilsson B, Bummig P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence clinical course, and prognostication in the pre-imatinib mesylate era – a populationbased study in western Sweden. *Cancer* 2005;103:821–829.
- Goettsch WC, Bos SD, Breekeveldts-Postma N, et al. Incidence of gastrointestinal stromal tumors is underestimated: result of a nation-wide study. *Eur J Cancer* 2005;41:2868–2872.
- Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlet) are common in adults and frequently show c-kit mutations. *Am J Surg Pathol* 2007;31:113–120.
- Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. *Hum Pathol* 2006;37:1527–1535.
- Rossi S, Gasparotto D, Toffolatti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. *Am J Surg Pathol* 2010;34:1480–1491.
- Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extraadrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. *Mayo Clin Proc* 1999;74:543–552.
- Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumors and pulmonary chondromas (Carney triad) and the dyad of paragangliomas and gastric stromal sarcomas (Carney–Stratakis syndrome): molecular genetics and clinical implications. *J Intern Med* 2009;266:43–52.
- Fuller CE, Williams GT. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). *Histopathology* 1991;19:1–11.
- Li FP, Fletcher JA, Heinrich MC, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. *J Clin Oncol* 2005;23:2735–2743.
- Postow MA, Robson ME. Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. *Clin Sarcoma Res* 2012;2:16.
- Miettinen MM, Corless CL, Debiec-Rychter M, et al. Gastrointestinal stromal tumors. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *Lyon, France: IARC*; 2013: 164–167.
- Fletcher CDM, Bermann JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumor: a consensus approach. *Hum Pathol* 2002;33:459–465.
- Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. *Semin Diagn Pathol* 2006;23:70–83.
- Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumors. *Hum Pathol* 2008;39:1411–1419.
- Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localized primary gastrointestinal stromal tumour: a retrospective analysis. *Lancet Oncol* 2009;10:1045–1052.
- Rossi S, Miceli R, Messerini L, et al. Natural history of imatinib-naïve GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. *Am J Surg Pathol* 2011;35:1646–1656.
- Joensuu H, Vehtari A, Riihimäki J, et al. Risk of gastrointestinal stromal tumour recurrence after surgery: an analysis of pooled population-based cohorts. *Lancet Oncol* 2012;13:265–274.
- Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. *Mod Pathol* 1998;11:728–734.
- West RB, Corless CL, Chen X, et al. The novel marker, *DOG1*, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of *KIT* or *PDGFRA* mutational status. *Am J Pathol* 2004;165:107–113.
- Novelli M, Rossi S, Rodriguez-Justo M, et al. *DOG1* and *CD117* are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. *Histopathology* 2010;57:259–270.
- Doyle LA, Nelson D, Heinrich MC, et al. Loss of succinate dehydrogenase subunit B (*SDHB*) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. *Histopathology* 2012;61:801–809.
- Wagner AJ, Remillard SP, Zhang YX, et al. Loss of expression of *SDHA* predicts *SDHA* mutations in gastrointestinal stromal tumors. *Mod Pathol* 2013;26:289–294.
- Ricci R, Dei Tos AP, Rindi G. GISTogram: a graphic presentation of the growing GIST complexity. *Virchows Arch* 2013;463:481–487.
- Nannini M, Biasco G, Astolfi A, et al. An overview on molecular biology of *KIT*/*PDGFRA* wild type (WT) gastrointestinal stromal tumours (GIST). *J Med Genet* 2013;50:653–661.
- Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking *KIT* and *PDGFRA* mutations. *Proc Natl Acad Sci U S A* 2011;108:314–318.
- Miettinen M, Killian JK, Wang ZF, et al. Immunohistochemical loss of succinate dehydrogenase subunit A (*SDHA*) in gastrointestinal stromal tumors (GISTs) signals *SDHA* germline mutation. *Am J Surg Pathol* 2013;37:234–240.
- Kinoshita K, Hirota S, Isozaki K, et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. *J Pathol* 2004;202:80–85.
- Maertens O, Prenen H, Debiec-Rychter M, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in *NF1* patients. *Hum Mol Genet* 2006;15:1015–1023.
- Agaram NP, Wong GC, Guo T, et al. Novel *V600E* *BRAF* mutations in imatinib-naïve and imatinib-resistant gastrointestinal stromal tumors. *Genes Chromosomes Cancer* 2008;47:853–859.
- Hostein I, Faur N, Primois C, et al. *BRAF* mutation status in gastrointestinal stromal tumors. *Am J Clin Pathol* 2010;133:141–148.
- Eriksson M, Reichardt P, Sundby Hall K, et al. Needle biopsy through the abdominal wall for the diagnosis of GIST – Does it pose any risk for tumor cell seeding and recurrence? Presented at: 2012 Connective Tissue Oncology Society Meeting; November 17, 2012; Prague.
- Plumb AA, Kochhar R, Leahy M, et al. Patterns of recurrence of gastrointestinal stromal tumour (GIST) following complete resection: implications for follow-up. *Clin Radiol* 2013;68:770–775.
- Edge S, Byrd DR, Compton CC, eds. *AJCC Cancer Staging Manual*. 7th ed. New York: Springer; 2010.
- Hohenberger P, Ronellenfitch U, Oladeji O, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. *Br J Surg* 2010;97:1854–1859.
- Jati A, Tatli S, Morgan JA, et al. Imaging features of bone metastases in patients with gastrointestinal stromal tumors. *Diagn Interv Radiol* 2012;18:391–396.
- Kaemmer DA, Otto J, Lassay L, et al. The Gist of literature on pediatric GIST: review of clinical presentation. *J Pediatr Hematol Oncol* 2009;31:108–112.
- Kim SY, Janeway K, Pappo A. Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches. *Curr Opin Oncol* 2010;22:347–350.
- Bruno M, Carucci P, Repici A, et al. The natural history of gastrointestinal subepithelial tumors arising from muscularis propria: an endoscopic ultrasound survey. *J Clin Gastroenterol* 2009;43:821–825.
- Gill KR, Camellini L, Conigliaro R, et al. The natural history of upper gastrointestinal subepithelial tumors: a multicenter endoscopic ultrasound survey. *J Clin Gastroenterol* 2009;43:723–726.
- Lim YJ, Son HJ, Lee JS, et al. Clinical course of subepithelial lesions detected on upper gastrointestinal endoscopy. *World J Gastroenterol* 2010;16:439–444.
- Karakousis GC, Singer S, Zheng J, et al. Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. *Ann Surg Oncol* 2011;18:1599–1605.
- Catena F, Di Battista M, Fusaroli P, et al. Laparoscopic treatment of gastric GIST: report of 21 cases and literature's review. *J Gastrointest Surg* 2008;12:561–568.
- Ohltani H, Maeda K, Noda E, et al. Meta-analysis of laparoscopic and open surgery for gastric gastrointestinal stromal tumor. *Anticancer Res* 2013;33:5031–5041.
- Frankel TL, Chang AE, Wong SL. Surgical options for localized and advanced gastrointestinal stromal tumors. *J Surg Oncol* 2011;104:882–887.
- DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 2000;231:51–58.
- McCarter MD, Antonescu CR, Ballman KV, et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. *J Am Coll Surg* 2012;215:53–59.
- Jakob J, Mussi C, Ronellenfitch U, et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. *Ann Surg Oncol* 2013;20:586–592.
- Mussi C, Schildhaus HU, Gronchi A, et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. *Clin Cancer Res* 2008;14:4550–4555.
- DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. *Lancet* 2009;373:1097–1104.

57. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. *JAMA* 2012a;307:1265–1272.
58. Casali PG, Le Cesne A, Poveda Velasco A, et al. Imatinib failure-free survival (FFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/ACITG/FSG/GEIS/ISC randomized controlled phase III trial. *J Clin Oncol* 2013;31:abstr 10500.
59. Casali PG, Fumagalli E, Gronchi A. Adjuvant therapy of gastrointestinal stromal tumors (GIST). *Curr Treat Options Oncol* 2012;13:277–284.
60. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. *J Clin Oncol* 2010;28:1247–1253.
61. Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). *Eur J Surg Oncol* 2009;35:739–745.
62. Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSC experience. *Ann Surg Oncol* 2013;20:2937–2943.
63. Koontz MZ, Visser BM, Kunz PL. Neoadjuvant imatinib for borderline resectable GIST. *J Natl Compr Canc Netw* 2012;10:1477–1482.
64. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. *Ann Surg Oncol* 2012;19:1074–1080.
65. Tirumani SH, Shinagare AB, Jagannathan JP, et al. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. *Eur J Surg Oncol* 2014;40:420–428.
66. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *N Engl J Med* 2001;344:1052–1056.
67. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *J Clin Oncol* 2008;26:620–625.
68. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet* 2004;364:1127–1134.
69. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *J Clin Oncol* 2008;26:626–632.
70. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. *J Clin Oncol* 2005;23:5795–5804.
71. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *J Clin Oncol* 2008;26:5360–5367.
72. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol* 2006;24:4764–4774.
73. Barnett CM, Corless CL, Heinrich MC. Gastrointestinal stromal tumors: molecular markers and genetic subtypes. *Hematol Oncol Clin North Am* 2013;27:871–888.
74. Janeway KA, Albritton KH, Van Den Abbeele AD, et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. *Pediatr Blood Cancer* 2009;52:767–771.
75. Le Cesne A, Ray-Coquard I, Bui BN, et al. French Sarcoma Group. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. *Lancet Oncol* 2010;11:942–949.
76. Patrikidou A, Chabaud S, Ray-Coquard I, et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. *Ann Oncol* 2013;24:1087–1093.
77. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. *Cancer Treat Rev* 2011;37:75–88.
78. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. *Ann Surg* 2007;245:347–352.
79. Sym SJ, Ryu MH, Lee JL, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). *J Surg Oncol* 2008;98:27–33.
80. Raut CP, Wang Q, Manola J, et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. *Ann Surg Oncol* 2010;17:407–415.
81. Mussi C, Ronellenfitch U, Jakob J, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? *Ann Oncol* 2010;21:403–408.
82. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. *Ann Surg Oncol* 2012;19:1074–1080.
83. Wang YP, Jie ZG, He YL, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. *Eur J Cancer* 2014;50:1772–1778.
84. Bamboat ZM, DeMatteo RP. Metastectomy for gastrointestinal stromal tumors. *J Surg Oncol* 2014;109:23–27.
85. Wang WL, Conley A, Reynoso D, et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. *Cancer Chemother Pharmacol* 2011;67:S15–S24.
86. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. *J Pathol* 2008;216:64–74.
87. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. *Clin Cancer Res* 2006;12:1743–1749.
88. Shankar S, vanSonnenberg E, Desai J, et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. *Radiology* 2005;235:892–898.
89. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. *Cancer Chemother Pharmacol* 2005;55:379–386.
90. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. *J Clin Oncol* 2009;27:3141–3147.
91. Zalcberg JR, Verweij J, Casali PG, et al. EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. *Eur J Cancer* 2005;41:1751–1757.
92. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 2006;368:1329–1338.
93. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol* 2008;26:5352–5359.
94. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. *Eur J Cancer* 2009;45:1959–1968.
95. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:295–302.
96. De Wit M, Boers-Doets CB, Saettini A, et al. Prevention and management of adverse events related to regorafenib. *Support Care Cancer* 2014;22:837–846.
97. Casali PG, Reichardt P, Kang Y, et al. Clinical benefit with regorafenib across subgroups and post-progression in patients with advanced gastrointestinal stromal tumor (GIST) after progression on imatinib (IM) and sunitinib (SU): phase 3 GRID trial update. *Ann Oncol* 2012;23:ix478.
98. Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2013;14:1175–1182.
99. Demetri GD, Jeffers M, Reichardt P, et al. Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: correlating genotype with clinical outcomes. *J Clin Oncol* 2013;31:abstr 10503.
100. Benjamin RS, Debiec-Rychter M, Le Cesne A, et al. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. *Semin Oncol* 2009;36:302–311.
101. Tirumani SH, Jagannathan JP, Krajewski KM, et al. Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective. *AJR Am J Roentgenol* 2013;201:801–810.
102. Van den Abbeele AD. The lessons of GIST—PET and PET/CT: a new paradigm for imaging. *Oncologist* 2008;13:8–13.
103. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–247.
104. Choi H, Chamsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. *J Clin Oncol* 2007;25:1753–1759.